Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C25H31NO3 |
Molecular Weight | 393.5185 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=C(OC2CCCC2)C=C(C=C1)[C@H]3CNC(=O)[C@H](CC4=CC(C)=CC=C4)C3
InChI
InChIKey=ABEJDMOBAFLQNJ-NHCUHLMSSA-N
InChI=1S/C25H31NO3/c1-17-6-5-7-18(12-17)13-20-14-21(16-26-25(20)27)19-10-11-23(28-2)24(15-19)29-22-8-3-4-9-22/h5-7,10-12,15,20-22H,3-4,8-9,13-14,16H2,1-2H3,(H,26,27)/t20-,21-/m1/s1
Molecular Formula | C25H31NO3 |
Molecular Weight | 393.5185 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Inflazyme Pharmaceuticals initially developed HT-0712 as a phosphodiesterase IV (PDE4) inhibitor with anti-inflammatory properties. Now the rights on this drug are wholly owned by Dart NeuroScience. January 2015, Dart NeuroScience completed a phase II trial of HT-0712 for the memory disorders, where were evaluated the efficacy in improving memory and cognitive performance.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2093863 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17823313 |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT02013310
HT-0712 capsules (50mg) administered once daily.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 05:00:26 GMT 2023
by
admin
on
Sat Dec 16 05:00:26 GMT 2023
|
Record UNII |
2O43FXG9IG
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
HT-0712
Created by
admin on Sat Dec 16 05:00:26 GMT 2023 , Edited by admin on Sat Dec 16 05:00:26 GMT 2023
|
PRIMARY | |||
|
DTXSID70893926
Created by
admin on Sat Dec 16 05:00:26 GMT 2023 , Edited by admin on Sat Dec 16 05:00:26 GMT 2023
|
PRIMARY | |||
|
2O43FXG9IG
Created by
admin on Sat Dec 16 05:00:26 GMT 2023 , Edited by admin on Sat Dec 16 05:00:26 GMT 2023
|
PRIMARY | |||
|
300000041442
Created by
admin on Sat Dec 16 05:00:26 GMT 2023 , Edited by admin on Sat Dec 16 05:00:26 GMT 2023
|
PRIMARY | |||
|
617720-02-2
Created by
admin on Sat Dec 16 05:00:26 GMT 2023 , Edited by admin on Sat Dec 16 05:00:26 GMT 2023
|
PRIMARY | |||
|
DB11650
Created by
admin on Sat Dec 16 05:00:26 GMT 2023 , Edited by admin on Sat Dec 16 05:00:26 GMT 2023
|
PRIMARY | |||
|
9865375
Created by
admin on Sat Dec 16 05:00:26 GMT 2023 , Edited by admin on Sat Dec 16 05:00:26 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
IC50
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|